Monogram
Developing a robotic surgical platform and patient-optimized 3D-printed orthopedic implants for joint replacement, combining 3D printing, machine vision, and robotics to enable mass personalization of implants.
- CEO / Founder
- Benjamin Sexson
- Team Size
- 11-50
- Stage
- Acquired
- Total Funding
- $60.248M
- Latest Round
- Series D
- Key Investors
- Bessemer Venture Partners; Foundry Group; True Ventures; Boldstart Ventures; SOSV; Hax
Technology & Products
Key Products
mBôs Surgical Robot (total knee arthroplasty); Patient-optimized 3D-printed orthopedic implants; Pre-operative imaging and surgical planning software
Technological Advantage
Exclusive license from Mount Sinai School of Medicine; 14 patent filings as of 2022 covering 3D printing, robotics, and automated digital image analysis; the proprietary combination of AM and surgical robotics creates a defensible barrier, though clinical and regulatory validation remains in early stages.
Differentiation
Value Proposition
Enables patient-optimized orthopedic implants at scale through an integrated 3D printing and robotic surgery platform, potentially reducing revision surgeries and improving patient outcomes while lowering long-term costs for hospitals through automated surgical workflows.
How They Differentiate
Unlike traditional implant lines from Stryker or Zimmer Biomet, Monogram's platform is designed for patient-specific mass personalization through an integrated AI-driven robotic system and 3D printing, with remote surgical planning capabilities. However, it remains at an early clinical stage versus established product portfolios.
Market & Competition
Target Customers
Orthopedic surgeons, hospitals, ambulatory surgery centers, and health systems performing joint replacement procedures.
Industry Verticals
Medical Devices; Orthopedics; Robotic Surgery
Competitors
Restor3d; LimaCorporate; Stryker
Growth & Milestones
Growth Metrics
founded: April 21, 2016 (incorporated as Monogram Arthroplasty Inc.; later Monogram Orthopaedics Inc.). funding: $17.2 million raised from over 5,000 investors (Reg A offering)
Major Milestones
2025: FDA 510(k) Clearance for Monogram mBôs TKA System; 2024: Named Orthopedic Joint Replacement Company of the Year by Medical Tech Outlook; submitted 510(k) application for mBôs TKA System clearance; 2023: Raised $17.2M Series D; listed on NASDAQ; received first purchase order; started verification phase; 2022: FDA clearance for Press-Fit CKS Total Knee; awarded NSF grant for novel tracking technology; closed $4.5M Series C; 2021: Raised $21.8M Series B; 2020: Raised $14.568M Series A; signed first distributor; reached 15 full-time employees; 2019: 3D printing mechanical testing; 2018: Nebraska knee studies; closed $1.148M seed round #2; 2017: UCLA hip studies; closed $1.032M seed round #1; first patent application published
Notable Customers
FDA clearance for mBone implant system; Clinical sites for robotic-assisted total knee arthroplasty